Glycoursodeoxycholic acid ameliorates diet-induced metabolic disorders with inhibiting endoplasmic reticulum stress. Issue 14 (30th July 2021)

• Record Type: Journal Article
• Authors: Cheng, Lele; Chen, Tao; Guo, Manyun; Liu, Peining; Qiao, Xiangrui; Wei, Yuanyuan; She, Jianqing; Li, Bolin; Xi, Wen; Zhou, Juan; Yuan, Zuyi; Wu, Yue; Liu, Junhui
• Is Part Of: Clinical science. Volume 135:Issue 14(2021)
• Page Start: 1689
• Page End: 1706
• Publication Date: 2021-07-30
• Subjects: Bile acids -- Endoplasmic reticulum stress -- Glycoursodeoxycholic acid -- Metabolic disorders; Medicine -- Periodicals; Biochemistry -- Periodicals; 616
• DOI: 10.1042/CS20210198
• Languages: English
• ISSNs: 0143-5221

Abstract

Abstract: Recent studies reveal that bile acid metabolite composition and its metabolism are changed in metabolic disorders, such as obesity, type 2 diabetes and metabolic associated fatty liver disease (MAFLD), yet its role and the mechanism remain largely unknown. In the present study, metabolomic analysis of 163 serum and stool samples of our metabolic disease cohort was performed, and we identified glycoursodeoxycholic acid (GUDCA), glycine-conjugated bile acid produced from intestinal bacteria, was decreased in both serum and stool samples from patients with hyperglycemia. RNA-sequencing and quantitative PCR results indicated that GUDCA alleviated endoplasmic reticulum (ER) stress in livers of high fat diet (HFD)-fed mice without alteration of liver metabolism. In vitro, GUDCA reduced palmitic acid induced-ER stress and -apoptosis, as well as stabilized calcium homeostasis. In vivo, GUDCA exerted effects on amelioration of HFD-induced insulin resistance and hepatic steatosis. In parallel, ER stress and apoptosis were decreased in GUDCA-treated mice as compared with vehicle-treated mice in liver. These findings demonstrate that reduced GUDCA is an indicator of hyperglycemia. Supplementation of GUDCA could be an option for the treatment of diet-induced metabolic disorders, including insulin resistance and hepatic steatosis, with inhibiting ER stress.